155 related articles for article (PubMed ID: 12687572)
1. Aquaporins in primary Sjögren's syndrome: comment on the articles by Steinfeld et al.
Waterman SA; Beroukas D; Hiscock J; Jonsson R; Gordon TP
Arthritis Rheum; 2003 Apr; 48(4):1167-8. PubMed ID: 12687572
[No Abstract] [Full Text] [Related]
2. Treatment with infliximab restores normal aquaporin 5 distribution in minor salivary glands of patients with Sjögren's syndrome.
Steinfeld SD; Appelboom T; Delporte C
Arthritis Rheum; 2002 Aug; 46(8):2249-51. PubMed ID: 12209534
[No Abstract] [Full Text] [Related]
3. Infliximab and primary Sjogren's syndrome: comment on the article by Mariette et al.
Fresko I; Seyahi E; Yurdakul S
Arthritis Rheum; 2004 Dec; 50(12):4077; author reply 4077-8. PubMed ID: 15593208
[No Abstract] [Full Text] [Related]
4. Successful treatment of Sjogren's syndrome with rituximab.
Touma Z; Sayad J; Arayssi T
Scand J Rheumatol; 2006; 35(4):323-5. PubMed ID: 16882600
[No Abstract] [Full Text] [Related]
5. Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles.
Ettefagh L; Nedorost S; Mirmirani P
Arch Dermatol; 2004 Aug; 140(8):1012. PubMed ID: 15313825
[No Abstract] [Full Text] [Related]
6. Will targeting B cells be the answer for Sjögren's syndrome?
Looney RJ
Arthritis Rheum; 2007 May; 56(5):1371-7. PubMed ID: 17469093
[No Abstract] [Full Text] [Related]
7. Rituximab therapy in primary Sjögren's syndrome.
Alcântara C; Gomes MJ; Ferreira C
Ann N Y Acad Sci; 2009 Sep; 1173():701-5. PubMed ID: 19758218
[TBL] [Abstract][Full Text] [Related]
8. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
Pijpe J; van Imhoff GW; Spijkervet FK; Roodenburg JL; Wolbink GJ; Mansour K; Vissink A; Kallenberg CG; Bootsma H
Arthritis Rheum; 2005 Sep; 52(9):2740-50. PubMed ID: 16142737
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of a patient with primary Sjögren's syndrome with Rituximab.
Ring T; Kallenbach M; Praetorius J; Nielsen S; Melgaard B
Clin Rheumatol; 2006 Nov; 25(6):891-4. PubMed ID: 16283417
[TBL] [Abstract][Full Text] [Related]
10. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.
Pers JO; Devauchelle V; Daridon C; Bendaoud B; Le Berre R; Bordron A; Hutin P; Renaudineau Y; Dueymes M; Loisel S; Berthou C; Saraux A; Youinou P
Arthritis Rheum; 2007 May; 56(5):1464-77. PubMed ID: 17469105
[TBL] [Abstract][Full Text] [Related]
11. Autoimmune hepatitis in primary Sjogren's syndrome: pathological study of the livers and labial salivary glands in 17 patients with primary Sjogren's syndrome.
Matsumoto T; Morizane T; Aoki Y; Yamasaki S; Nakajima M; Enomoto N; Kobayashi S; Hashimoto H
Pathol Int; 2005 Feb; 55(2):70-6. PubMed ID: 15693852
[TBL] [Abstract][Full Text] [Related]
12. Sjögren's syndrome presenting with a minor salivary gland mass.
Kemker BJ; Dayal VS; DeMay RM
J Otolaryngol; 1998 Oct; 27(5):298-300. PubMed ID: 9800630
[No Abstract] [Full Text] [Related]
13. Infliximab in primary Sjögren's syndrome: one-year followup.
Steinfeld SD; Demols P; Appelboom T
Arthritis Rheum; 2002 Dec; 46(12):3301-3. PubMed ID: 12483735
[TBL] [Abstract][Full Text] [Related]
14. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
Mariette X; Ravaud P; Steinfeld S; Baron G; Goetz J; Hachulla E; Combe B; Puéchal X; Pennec Y; Sauvezie B; Perdriger A; Hayem G; Janin A; Sibilia J
Arthritis Rheum; 2004 Apr; 50(4):1270-6. PubMed ID: 15077311
[TBL] [Abstract][Full Text] [Related]
15. Extremely high salivary β(2) -microglobulin and Na(+) levels in a Sjögren syndrome patient.
Asashima H; Inokuma S; Nakachi S; Matsuo Y; Rokutanda R; Hagiwara K; Kobayashi S
Int J Rheum Dis; 2012 Apr; 15(2):e31-3. PubMed ID: 22462432
[No Abstract] [Full Text] [Related]
16. The therapy of Sjogren's syndrome: a review.
Coaccioli S; Giuliani M; Puxeddu A
Clin Ter; 2007; 158(5):453-6. PubMed ID: 18062353
[TBL] [Abstract][Full Text] [Related]
17. [TNF-alpha inhibitors].
Fain O
Rev Prat; 2003 Nov; 53(18):1989-90. PubMed ID: 15008210
[No Abstract] [Full Text] [Related]
18. Maintenance of rituximab treatment in a patient with primary Sjögren's syndrome.
Lehner GF; Brunner-Palka M; Rettenbacher T; Schmidauer R; Herold M
Rheumatology (Oxford); 2014 Jul; 53(7):1349-50. PubMed ID: 24446469
[No Abstract] [Full Text] [Related]
19. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome.
Lavie F; Miceli-Richard C; Quillard J; Roux S; Leclerc P; Mariette X
J Pathol; 2004 Apr; 202(4):496-502. PubMed ID: 15095277
[TBL] [Abstract][Full Text] [Related]
20. Issues related to clinical trials of oral and biologic disease-modifying agents for Sjögren's syndrome.
Carsons SE
Rheum Dis Clin North Am; 2008 Nov; 34(4):1011-23, x. PubMed ID: 18984419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
